Related Experiment Video
Updated: Nov 5, 2025

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
Published on: April 1, 2015
Bortezomib for treatment-refractory autoimmune haemolytic anaemia following multivisceral transplantation
Darren Wong1,2, William Thomas3, Andrew Butler4
1Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, UK darren.wong@austin.org.au.
Abstract:
A 25-year-old man who received alemtuzumab as induction therapy for a multivisceral transplant experienced delayed onset of warm autoimmune haemolytic anaemia and neutropaenia. Serological testing and bone marrow biopsy excluded alternative causes. Haemolysis was refractory to standard therapies including corticosteroids, intravenous immunoglobulin and rituximab. The patient was successfully treated with bortezomib, a proteasome inhibitor, and has remained well as an outpatient without evidence of ongoing haemolysis.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Treatment Resistant Cancers
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration

